Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636998 | 0.89 | SNCA (0.49) | MEN1GAAMAPTHTTKMT2A | |
| SCHEMBL9428199 | 0.85 | NOX1 (0.46) | MEN1MAPTKMT2AALDH1A1NOX1 | |
| SCHEMBL9171801 | 0.81 | MAPT (0.54) | MEN1GAAMAPTHTTKMT2A | |
| SCHEMBL9427946 | 0.77 | MAPT (0.44) | MEN1GAAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL10772188 | 0.71 | GAA (0.44) | MEN1GAAMAPTHTTKMT2A | |
| SCHEMBL7430660 | 0.70 | MEN1 (0.52) | MEN1GAAMAPTHTTKMT2A | |
| Hydrochloric Acid SCHEMBL11369211 | 0.69 | BCHE (0.42) | — | |
| SCHEMBL2609258 | 0.69 | NOX1 (0.66) | MEN1GAAMAPTHTTKMT2A | |
| SCHEMBL5746504 | 0.69 | NPC1 (0.69) | MEN1GAAMAPTHTTKMT2A | |
| SCHEMBL5746497 | 0.69 | NPC1 (0.69) | MEN1GAAMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60025981-A | — | — | None | — | — | JP | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| EP-1025080-B1 | PROCESS FOR THE RECYCLE OF A WASTE PRODUCT OF DILTIAZEM SYNTHESIS | ZAMBON SPA (IT) | 2003-01-08 | — | — | EP | disclosed |
| US-6114523-A | Process for the recycle of a waste product of diltiazem synthesis | ZAMON GROUP S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
| EP-1025080-A1 | PROCESS FOR THE RECYCLE OF A WASTE PRODUCT OF DILTIAZEM SYNTHESIS | ZAMBON GROUP S.p.A. (IT) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020603-A1 | PROCESS FOR THE RECYCLE OF A WASTE PRODUCT OF DILTIAZEM SYNTHESIS | ZAMBON GROUP S.P.A. (IT) | 1999-04-29 | — | — | WO | disclosed |
| US-5310904-A | Intermediate | TANABE SEIYAKU CO., LTD. (JP) | 1994-05-10 | — | — | US | disclosed |
| EP-0551076-A1 | Process for preparing optically active benzothiazepine compounds by asymmetric reduction | TANABE SEIYAKU CO., LTD. (JP) | 1993-07-14 | — | — | EP | disclosed |
| JP-S6025981-A | BENZOTHIAZEPINE DERIVATIVE AND ITS PREPARATION | TANABE SEIYAKU CO LTD | 1985-02-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | MEN1 3169/4885GAA 425/4885MAPT 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.